Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421044 · ClinicalTrials.gov registry record · Phase 1
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
A Phase 1 study of Tumors and Advanced Malignancies, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 3
- Study locations
NCT00421044: Completed Phase 1 study of Tumors and Advanced Malignancies, sponsored by Novartis Pharmaceuticals.
NCT00421044 is a Phase 1 study of Tumors and Advanced Malignancies that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants, below the 199-participant average among 20 other Tumors trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00421044, a Phase 1 study of Tumors and Advanced Malignancies, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
Conditions Studied
Interventions
- DRUG Patupilone/EPO906
Study Locations (3)
Texas
- Institute for Drug Development Cancer Therapy & Research Center/The University of Texas Health Science Center - San Antonio
- South Texas Accelerated Research Therapeutics - San Antonio
California
- University of California San Diego/Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-05 |
| Phase | Phase 1 |
What the finished NCT00421044 record still lists
NCT00421044 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 199-participant average among 20 other Tumors trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Patupilone/EPO906 is the first listed.
NCT00421044 reports a single indexed study location in Texas, California.
Frequently Asked Questions
What is clinical trial NCT00421044 about?
NCT00421044 is a clinical study titled "A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function". Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
What is the current status of trial NCT00421044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-05.
What conditions does trial NCT00421044 study?
This clinical trial studies the following conditions: Tumors, Advanced Malignancies.
What interventions are being tested in trial NCT00421044?
The interventions under investigation include: Patupilone/EPO906 (DRUG).
Who is sponsoring clinical trial NCT00421044?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00421044 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00421044's enrollment target sits among peer trials
14 21st of 20 the lowest of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia